RECOMBINANT ANTIBODIES AS INTRA VAGINAL SPERMICIDES

世界人口预计将达到100亿人， 到2050年，将比目前人口增加75%以上。 有必要开发新的避孕选择， 所有人都能获得避孕措施， 社会、经济或教育的局限性。电流 文献表明市售杀精制剂用于宫颈癌 和阴道刺激，导致病变和获得 性传播疾病这些杀精剂的重新评估， FDA可能会导致成本增加或从 市场新型廉价杀精剂，安全性提高， 必须提高效力。本研究的目的 一项建议是开发一种基于抗精子的杀精剂， 单克隆抗体S19。该mAb抑制人类精子功能 和配子的相互作用。拟议的I期研究将 测试表达和纯化足够的可行性 一定量的生物活性重组S19抗体。朝向 重组S19抗体的表达，S19重链和 克隆并测序轻链可变区。的 本研究计划的具体目的是表达重组 S19抗体的抗原结合活性，并评价该抗体的抗原结合活性。 重组抗体这项研究将提供一个模型， 抗精子抗体免疫避孕药 S19 mAb抑制人精子 功能和配子相互作用，因此是一个有吸引力的 用于开发基于抗体的阴道内 杀精剂拟开展的研究将检测重组S19 ScFv 以确定其作为S19廉价来源的可行性 抗体的

World population is predicted to reach 10 billion people by the year 2050, increasing more than 75% over the current population. Development of new contraceptive options is necessary to provide accessible birth control to all individuals regardless of sociological, financial, or educational limitations. Current literature implicates marketed spermicidal formulations in cervical and vaginal irritation leading to lesions and acquisition of sexually transmitted diseases. Reassessment of these spermicides by the FDA may result in increased costs or their removal from the market. New, inexpensive spermicides with improved safety and effectiveness must be developed. The objective of this research proposal is the development of a spermicide based on an anti-sperm monoclonal antibody, S19. This mAb inhibits human sperm function and gamete interactions in vitro. The proposed Phase l study will test the feasibility of expressing and purifying sufficient quantities of biologically active recombinant S19 antibody. Towards the expression of a recombinant S19 antibody, the S19 heavy and light chain variable regions were cloned and sequenced. The specific aims of this research proposal are to express recombinant S19 antibody and evaluate the antigen-binding activity of the recombinant antibody. The proposed research will provide a model for anti-sperm antibody immunocontraceptives. PROPOSED COMMERCIAL APPLICATIONS The S19 mAb inhibits human sperm function and gamete interactions and is therefore an attractive candidate for the development of an antibody-based, intravaginal spermicide. The proposed studies will examine recombinant S19 ScFv to determine its feasibility as an inexpensive source of the S19 antibody.